Mitoguazone

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 205979

CAS#: 459-86-9

Description: Mitoguazone is a guanylhydrazone with potential antineoplastic activity. Mitoguazone competitively inhibits S-adenosyl-L-methionine decarboxylase (SAMD), an enzyme involved in the synthesis of polyamines, resulting in decreased proliferation of tumor cells, antimitochondrial effects, and p53-independent apoptosis. Polyamines, specifically spermine and spermidine, are essential for thymidine kinase production, DNA synthesis, and cell proliferation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).


Price and Availability

Size
Price

10mg
Not available
100mg
Not available
1g
Ask price
Size
Price

25mg
Not available
200mg
Not available
2g
Ask price
Size
Price

50mg
Not available
500mg
Not available
5g
Ask price

Mitoguazone is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 205979
Name: Mitoguazone
CAS#: 459-86-9
Chemical Formula: C5H12N8
Exact Mass: 184.11849
Molecular Weight: 184.20238
Elemental Analysis: C, 32.60; H, 6.57; N, 60.83


Synonym: Mitoguazone; MeGAG; methylG; methylGAG; MGBG; MGGH; DRG0223; NSC32946.

IUPAC/Chemical Name: (2E,2'E)-2,2'-(propane-1,2-diylidene)bis(hydrazinecarboximidamide)

InChi Key: MXWHMTNPTTVWDM-NXOFHUPFSA-N

InChi Code: InChI=1S/C5H12N8/c1-3(11-13-5(8)9)2-10-12-4(6)7/h2H,1H3,(H4,6,7,12)(H4,8,9,13)/b10-2+,11-3+

SMILES Code: CC(/C=N/NC(N)=N)=N\NC(N)=N


Technical Data

Appearance:
Solid powder

Purity:
>98%

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>5 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

  
 
 
 


References

1: Ferioli ME, Bottone MG, Soldani C, Pellicciari C. Administration of the antitumor drug mitoguazone protects normal thymocytes against spontaneous and etoposide-induced apoptosis. Cell Mol Life Sci. 2004 Nov;61(21):2767-73. PubMed PMID: 15549180.

2: Ferioli ME, Berselli D, Caimi S. Effect of mitoguazone on polyamine oxidase activity in rat liver. Toxicol Appl Pharmacol. 2004 Dec 1;201(2):105-11. PubMed PMID: 15541750.

3: Tulpule A, Espina BM, Pedro Santabarbara AB, Palmer M, Schiflett J, Boswell W, Smith S, Levine AM. Treatment of AIDS related non-Hodgkin's lymphoma with combination mitoguazone dihydrochloride and low dose CHOP chemotherapy: results of a phase II study. Invest New Drugs. 2004 Jan;22(1):63-8. PubMed PMID: 14707495.

4: Ishmael DR, Chen WR, Hamilton SA, Liu H, Nordquist RE. A phase I human trial of mitoguazone and gemcitabine sequential bi-weekly treatment of cancer patients. Cancer Invest. 2003;21(4):542-9. PubMed PMID: 14533444.

5: Cheng CL, Lin EG, Chou CH. Rapid and sensitive quantitation of the antiproliferative agent mitoguazone in small volumes of plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Aug 15;793(2):281-9. PubMed PMID: 12906902.

6: Ishmael DR, Chen WR, Nordquist JA, Liu H, Nordquist RE. Synergistic effect of sequential administration of mitoguazone (MGBG) and gemcitabine in treating tissue cultured human breast cancer cells and mammary rat tumors. Cancer Invest. 2003 Apr;21(2):217-26. PubMed PMID: 12743987.

7: Ferioli ME, Armanni A. Polyamine oxidase activity in rats treated with mitoguazone: specific and permanent decrease in thymus. Amino Acids. 2003;24(1-2):187-94. PubMed PMID: 12624752.

8: Aurlien E, Holte H, Kvaløy S, Jakobsen E, Rusten LS, Kvalheim G. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients. Eur J Haematol Suppl. 2001 Jul;64:14-20. PubMed PMID: 11486395.

9: Wiernik PH, Gordon LI, Oken MM, Harris JE, O'Connell MJ. Evaluation of mitoguazone in patients with refractory chronic lymphocytic leukemia: a phase II study (P-H482) of the Eastern Cooperative Oncology Group. Leuk Lymphoma. 1999 Oct;35(3-4):375-7. PubMed PMID: 10706462.

10: Davidson K, Petit T, Izbicka E, Koester S, Von Hoff DD. Mitoguazone induces apoptosis via a p53-independent mechanism. Anticancer Drugs. 1998 Aug;9(7):635-40. PubMed PMID: 9773808.